Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

13.49EUR
9 Dec 2016
Change (% chg)

€0.31 (+2.35%)
Prev Close
€13.18
Open
€13.22
Day's High
€13.57
Day's Low
€13.20
Volume
208,303
Avg. Vol
169,922
52-wk High
€19.09
52-wk Low
€12.13

Select another date:

Thu, Nov 24 2016

BRIEF-Almirall reaches agreement with employees for restructuring in Spain

* Says reaches agreement to implement restructuring plan in Spain, reduces to 102 from 121 a number of employees affected

BRIEF-Almirall reports 9-month net profit up 41 percent

* Reports 9-month EBITDA up 6.5 percent at 183.8 million euros ($203.4 million) versus 172.6 million euros year ago

BRIEF-Almirall presents restructuring plan affecting 121 jobs

* Presents restructuring plan in Spain affecting up to 121 jobs

BRIEF-Almirall announces data from pivotal phase-3 clinical trials with inhibitor to treat psoriasis

* Announces results from two pivotal phase-3 clinical trials (reSURFACE 1 and 2) achieving primary endpoint of Tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis Source text for Eikon:

BRIEF-Almirall announces positive phase III results for drug against psoriasis

* Announces positive results from the phase III trial showing efficacy of dimethyl fumarate, a new systemic oral drug for patients with chronic plaque psoriasis

BRIEF-Almirall signs license deal with Sun Pharma for psoriasis treatment

* Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis

BRIEF-Almirall reports H1 net profit up at 80.5 million euros

* H1 net profit 80.5 million euros ($88.53 million) versus 58.8 million euros year ago

BRIEF-Almirall H1 net profit 80.5 mln euros, up 37 pct year on year

* H1 net profit 80.5 million euros versus 58.8 million euros year ago

BRIEF-Almirall announces global licensing deal with Patagonia for congenital ichthyosis

* Announces global licensing deal with Patagonia Pharmaceuticals for congenital ichthyosis

Spain's Almirall eyes Valeant skin drugs to boost dermatology

MADRID Spanish drugmaker Almirall, which is building up its business in skin treatments, could be interested in acquiring dermatology assets from Canada's Valeant Pharmaceuticals, the head of the Barcelona-based company said on Monday. Valeant is looking at divesting various products as it tries to reduce its massive debt load, with new CEO Joe Papa open to selling a range of assets if the price is right.

Select another date: